# US 2010/0166735 A1 · Methods and compositions for reduction of side effects of therapeutic treatments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166735 A1
- Document ID: US20100166735A1
- Status: Published application
- Kind: A1
- Application number: 12/534,928
- Filed: 2009-08-04
- Published: 2010-07-01
- Earliest claimed: 2007-04-02
- Inventors: Maryka Quik; Donato Di Monte; J. William Langston
- Web page: https://patentgrep.com/patent/US20100166735A1

## CPC

- A61K 31/465: Nicotine; Derivatives thereof
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment.

## Claims

### Claim at position 1

1-121. (canceled)

### Claim 122

A method for reducing drug-induced dyskinesia comprising administering to a human in need of treatment with a drug an amount of a nicotinic receptor agonist sufficient to reduce dyskinesia induced by said drug.

### Claim 123 (depends on 122)

The method of claim 122 wherein the amount of nicotinic receptor agonist is sufficient to reduce said dyskinesia at least about 30%.

### Claim 124 (depends on 122)

The method of claim 122 wherein said dyskinesia is induced by a Parkinson's disease treatment.

### Claim 125 (depends on 124)

The method of claim 124 wherein said Parkinson's disease treatment is a treatment with a dopaminergic agent.

### Claim 126 (depends on 125)

The method of claim 125 wherein said dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist.

### Claim 127 (depends on 125)

The method of claim 125 wherein said dopaminergic agent comprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline, ropinorole, apomorphine or a combination thereof.

### Claim 128 (depends on 127)

The method of claim 127 wherein said dopaminergic agent is levodopa.

### Claim 129 (depends on 122)

The method of claim 122 wherein said agonist is selected from the group consisting of a simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, an antibody fragment, a vitamin derivative, a carbohydrate and a toxin.

### Claim 130 (depends on 122)

The method of claim 122 wherein said agonist is selected from the group consisting of nicotine, conotoxinM11, epibatidine, A-85380, cytisine, lobeline, anabasine, SIB-1508Y, SIB-1553A, ABT-418, ABT-594, ABT-894, TC-2403, TC-2559, RJR-2403, SSR180711, GTS-21 and varenicline.

### Claim 131 (depends on 130)

The method of claim 130 wherein said agonist is nicotine

### Claim 132 (depends on 122)

The method of claim 122 wherein said nicotinic receptor agonist modulates a nicotinic receptor comprising at least one a subunit or a nicotinic receptor comprising at least one a subunit and at least one 13 subunit.

### Claim 133 (depends on 132)

The method of claim 132 wherein said α subunit is selected from the group consisting of α2, α3, α4, α5, α6, α7, α8, α9, and α10 and wherein said β subunit is selected from the group consisting of β2, β3 and β4.

### Claim 134 (depends on 133)

The method of claim 133 wherein said a subunit is selected from the group consisting of a β3, β4 and β6.

### Claim 135 (depends on 132)

The method of claim 132 wherein said nicotinic receptor agonist modulates a nicotinic receptor comprising subunits selected from the group consisting of β4β2, α6β2, α4α6β2, α4α5β2, α4α6β2β3, α6β2β3 and α4α2β2.

### Claim 136 (depends on 132)

The method of claim 132 wherein said nicotinic receptor agonist modulates a nicotinic receptor comprising subunits selected from the group consisting of α4 and α7.

### Claim 137 (depends on 122)

The method of claim 122 wherein said subject suffers from a condition selected from the group consisting of Parkinson and Alzheimer's disease.

### Claim 138 (depends on 137)

The method of claim 137 wherein said condition is Parkinson's disease.

### Claim 139 (depends on 122)

The method of claim 122 wherein said administration comprises a single dose of said nicotinic receptor agonist.

### Claim 140 (depends on 122)

The method of claim 122 wherein said administration comprises multiple doses of said nicotinic receptor agonist.

### Claim at position 21

141-152. (canceled)

### Claim 153 (depends on 122)

The method of claim 122 wherein the administering of said nicotine receptor agonist comprises oral administration.
